Research
My research focuses on improving the treatment of tuberculosis, ranging from evaluation of the value of preclinical models through pharmacokinetic-pharmacodynamic studies and clinical trials to evidence synthesis and policy.
Research groups
Research grants
Academia and Industry United Innovation and Treatment for Tuberculosis ( UNITE4TB)
EUROPEAN COMMISSION
June 2021 - May 2028
PanACEA Biomarker Extension Project (PANBIOME)
EUROPEAN AND DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP) - (NETHERLANDS)
January 2013 - June 2015
Randomised trial of high-dose rifampin in patients with new, smear-positive TB
NATIONAL INSTITUTES OF HEALTH (USA)
August 2011 - July 2017
Model-based preclinical development of anti-tuberculosis drug combinations (preDICT-TB)
EUROPEAN COMMISSION
May 2012 - October 2017
Population pharmacokinetic-pharmacodynamic modelling to optimise treatments for HIV,TB and malaria
WELLCOME TRUST (UK)
November 2008 - October 2012
Modulation of TB-HIV drug interaction by host genetic influences
MEDICAL RESEARCH COUNCIL
July 2010 - June 2013
Wellcome Trust Clinical PhD Programme - Derek Sloan: Understanding mycobacterial persistence in sputum during treatment for tuberculosis
WELLCOME TRUST (UK)
August 2009 - July 2012
Investigation into the relationship between pharmacological and immunological responses to tuberculosis treatment and risk of early death
THE BRITISH INFECTION ASSOCIATION (UK)
January 2013 - August 2014
Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a multi-centre, randomised, double blind, placebo controlled trial (the ARREST trial).
DEPARTMENT OF HEALTH & SOCIAL CARE (UK)
October 2012 - June 2016